Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro10 Extension Study in PID
NCT00322556Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Nov 2005
- Primary completion
- Apr 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of intravenous immunoglobulin G in agammaglobulinemia, immunoglobulin G deficiency, common variable immunodeficiency (CVID) and 1 more, sponsored by CSL Limited. Primary endpoints: The Proportion of Infusions With One or More Temporally-associated Adverse Events (AEs), Influence of Infusion Rate on Temporally-Associated AEs and 2 more. Started Nov 2005; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
agammaglobulinemiaimmunoglobulin G deficiencycommon variable immunodeficiency (CVID)X-linked agammaglobulinemia (XLA)
Beyond the preview
Go deeper on NCT00322556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322556.